

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

[Processa Pharmaceuticals, Inc.](#)

(Name of Issuer)

[Common Stock, par value \\$0.0001 per share](#)

(Title of Class of Securities)

[74275C403](#)

(CUSIP Number)

[08/03/2026](#)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP [74275C403](#)
Number(s):

1	Names of Reporting Persons Soleus Capital Master Fund, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 160,943.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 160,943.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 160,943.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) FI	

Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus Capital Master Fund, L.P. ("Master Fund"). Soleus Capital, LLC ("Soleus Capital") is the sole general partner of Master Fund, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, Soleus Capital Management, L.P. ("SCM") is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

(2) The percentage set forth in row 11 is calculated based upon 2,793,386 shares of the common stock of Processa Pharmaceuticals, Inc. (the "Issuer") outstanding as of August 7, 2026, as reported on the cover of the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 14, 2026 (the "Form 10-Q").

SCHEDULE 13G

CUSIP 74275C403
Number(s):

1	Names of Reporting Persons Soleus Capital, LLC
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 160,943.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 160,943.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 160,943.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

(2) The percentage set forth in row 11 is calculated based upon 2,793,386 shares of the common stock of the Issuer outstanding as of August 7, 2026, as set forth on the cover of the Form 10-Q.

SCHEDULE 13G

CUSIP 74275C403
Number(s):

1	Names of Reporting Persons Soleus Capital Group, LLC
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 160,943.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 160,943.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 160,943.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

(2) The percentage set forth in row 11 is calculated based upon 2,793,386 shares of the common stock of the Issuer outstanding as of August 7, 2026, as set forth on the cover of the Form 10-Q.

SCHEDULE 13G

CUSIP 74275C403
Number(s):

1	Names of Reporting Persons Soleus Capital Management, L.P.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 160,943.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 160,943.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 160,943.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

(2) The percentage set forth in row 11 is calculated based upon 2,793,386 shares of the common stock of the Issuer outstanding as of August 7, 2026, as set forth on the cover of the Form 10-Q.

SCHEDULE 13G

CUSIP 74275C403
Number(s):

1	Names of Reporting Persons Soleus GP, LLC
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 160,943.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 160,943.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 160,943.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

(2) The percentage set forth in row 11 is calculated based upon 2,793,386 shares of the common stock of the Issuer outstanding as of August 7, 2026, as set forth on the cover of the Form 10-Q.

SCHEDULE 13G

CUSIP 74275C403
Number(s):

1	Names of Reporting Persons Guy Levy
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 160,943.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 160,943.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 160,943.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

(2) The percentage set forth in row 11 is calculated based upon 2,793,386 shares of the common stock of the Issuer outstanding as of August 7, 2026, as set forth on the cover of the Form 10-Q.

SCHEDULE 13G

Item 1.

(a) **Name of issuer:**

Processa Pharmaceuticals, Inc.

(b) **Address of issuer's principal executive offices:**

601 21st Street, Suite 300, Vero Beach, FL 32960

Item 2.

(a) **Name of person filing:**

Soleus Capital Master Fund, L.P.
Soleus Capital, LLC
Soleus Capital Group, LLC
Soleus Capital Management, L.P.
Soleus GP, LLC
Guy Levy

(b) **Address or principal business office or, if none, residence:**

Soleus Capital Master Fund, L.P., 100 Field Point Road, Suite 200, Greenwich, CT 06830
Soleus Capital, LLC, 100 Field Point Road, Suite 200, Greenwich, CT 06830
Soleus Capital Group, LLC, 100 Field Point Road, Suite 200, Greenwich, CT 06830
Soleus Capital Management, L.P., 100 Field Point Road, Suite 200, Greenwich, CT 06830
Soleus GP, LLC, 100 Field Point Road, Suite 200, Greenwich, CT 06830
Guy Levy, c/o Soleus Capital Management, L.P., 100 Field Point Road, Suite 200, Greenwich, CT 06830

(c) **Citizenship:**
Soleus Capital Master Fund, L.P. - Cayman Islands
Soleus Capital, LLC - Delaware
Soleus Capital Group, LLC - Delaware
Soleus Capital Management, L.P. - Delaware
Soleus GP, LLC - Delaware
Guy Levy - United States

(d) **Title of class of securities:**
Common Stock, par value \$0.0001 per share

(e) **CUSIP Number(s):**
74275C403

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) **Amount beneficially owned:**
The information in rows 5 through 9 and 11 on the cover pages to this Schedule 13G, including the footnotes thereto, is hereby incorporated by reference.
160,943

(b) **Percent of class:**
5.8 %

(c) **Number of shares as to which the person has:**

(i) **Sole power to vote or to direct the vote:**
0

(ii) **Shared power to vote or to direct the vote:**
160,943

(iii) **Sole power to dispose or to direct the disposition of:**
0

(iv) **Shared power to dispose or to direct the disposition of:**
160,943

Item 5. Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Soleus Capital Master Fund, L.P.

Signature: /s/ Guy Levy

Name/Title: Guy Levy / Managing Member of the Managing Member of the General Partner of Soleus Capital Master Fund, L.P.

Date: 08/18/2026

Soleus Capital, LLC

Signature: /s/ Guy Levy

Name/Title: Guy Levy / Managing Member of the Managing Member of Soleus Capital, LLC

Date: 08/18/2026

Soleus Capital Group, LLC

Signature: /s/ Guy Levy

Name/Title: Guy Levy / Managing Member

Date: 08/18/2026

Soleus Capital Management, L.P.

Signature: /s/ Guy Levy

Name/Title: Guy Levy / Managing Member of the General Partner of Soleus Capital Management, L.P.

Date: 08/18/2026

Soleus GP, LLC

Signature: /s/ Guy Levy

Name/Title: Guy Levy / Managing Member

Date: 08/18/2026

Guy Levy

Signature: /s/ Guy Levy

Name/Title: Guy Levy / Individual

Date: 08/18/2026

Exhibit Information

Exhibit 99.A - Joint Filing Agreement

EXHIBIT A
Joint Filing Agreement

Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, Soleus Capital Management, L.P., a Delaware limited partnership, Soleus GP, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

Date: August 18, 2026

Soleus Capital Master Fund, L.P.

By: Soleus Capital, LLC, its General Partner

By: Soleus Capital Group, LLC, its Managing Manager

By: /s/ Guy Levy

Name: Guy Levy

Title: Managing Member

Date: August 18, 2026

Soleus Capital, LLC

By: Soleus Capital Group, LLC, its Managing Manager

By: /s/ Guy Levy

Name: Guy Levy

Title: Managing Member

Date: August 18, 2026

Soleus Capital Group, LLC

By: /s/ Guy Levy

Name: Guy Levy

Title: Managing Member

Date: August 18, 2026

Soleus Capital Management, L.P.

By: Soleus GP, LLC, its General Partner

By: /s/ Guy Levy

Name: Guy Levy

Title: Managing Member

Date: August 18, 2026

Soleus GP, LLC

By: /s/ Guy Levy

Name: Guy Levy

Title: Managing Member

Date: August 18, 2026

/s/ Guy Levy

Name: Guy Levy